MedTrace Logo

Amnis Therapeutics Thrombectomy Device-First in Man (FIM) Safety and Performance Study

NCT02994563 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2022-07-25

No results posted yet for this study

Summary

Prospective, single-arm, open label, Safety and Performance clinical investigation.

Conditions

Interventions

DEVICE

Thrombectomy Device

The Amnis Thrombectomy Device is intended to restore blood flow by removing thrombus from intracranial vessels in patients experiencing ischemic stroke

Sponsors & Collaborators

  • Amnis Therapeutics

    lead INDUSTRY

Principal Investigators

  • Tommy Andersson, M.D.; Ph.D. · Karolinska Institute, Neuroradiology Clinic, Stockholm, Sweden

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-07
Primary Completion
2021-02-25
Completion
2021-03-01

Countries

  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02994563 on ClinicalTrials.gov